Patton Curtis L. 4
4 · Tevogen Bio Holdings Inc. · Filed Jul 10, 2026
Research Summary
AI-generated summary of this filing
Tevogen (TVGN) Director Curtis L. Patton Receives 40,000-Share Award
What Happened
Curtis L. Patton, a director of Tevogen Bio Holdings, was granted 40,000 restricted shares on July 10, 2026 (transaction code A). The shares were issued at $0.00 per share (total reported acquisition value $0). This was a grant/award of restricted stock rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-07-10 (filed the same day)
- Transaction type/code: Grant/Award (A) of 40,000 restricted shares at $0.00 (total $0)
- Shares owned after transaction: Not specified in the filing
- Vesting/conditions (footnote F1): The award vests in three equal installments upon the earlier of each anniversary (1st, 2nd, 3rd) and the company achieving cumulative revenue milestones of $50M, $100M, and $150M respectively, provided Patton remains in service on each applicable vesting date.
- Timeliness: Filing shows the transaction and report date as 2026-07-10 (no late filing indicated)
Context
Restricted stock awards are common compensation for directors and are subject to vesting and service requirements; they do not represent an immediate sale or cash out. Because vesting here is tied to both tenure and company revenue milestones, the shares may not become freely tradable until those conditions are met.
Insider Transaction Report
Form 4
Patton Curtis L.
Director
Transactions
- Award
Common Stock
[F1]2026-07-10+40,000→ 64,192 total
Footnotes (1)
- [F1]Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which vests in three equal installments upon the earlier of each of (i) the first anniversary of the grant date and the Issuer having aggregate revenue of $50 million since the grant date, (ii) the second anniversary of the grant date and the Issuer having aggregate revenue of $100 million since the grant date, and (ii) the third anniversary of the grant date and the Issuer having aggregate revenue of $150 million since the grant date, provided that the reporting person remains in service with the Issuer on the applicable vesting date.
Signature
/s/ Kirti Desai, Attorney-in-Fact|2026-07-10